Human Podocyte Generation via Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The availability of large numbers of normal terminally differentiated human podocytes is limited, as existing protocols for isolating primary podocytes cannot expand them significantly, and other sources, such as podocyte cell lines, often show poor differentiation potential or are of non-human origin, hindering applications requiring large numbers of cells.
Innovation Solution
Generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor, optionally with additional factors like BMP4, BMP7, lysophosphatidic acid, or gamma-secretase inhibitor, under serum-free conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If primary podocytes are isolated from kidneys using existing protocols, then podocyte purity is maintained, but the number of cells cannot be expanded to significant numbers
Solution Approach 1:
The patent uses nephron progenitor cells as an intermediate stage before terminal podocyte differentiation. These progenitor cells are first generated from pluripotent stem cells under specific conditions (activin A, BMP4, FGF2), then subsequently differentiated into podocytes using inhibitors (FGF, BMP, WNT pathway inhibitors). This two-stage preliminary action enables expansion of cell numbers while maintaining differentiation potential.
Solution Approach 2:
The patent employs systematic parameter changes in signaling pathway inhibition to control cell fate. Specifically, it uses FGF pathway inhibitor (PD173099), BMP pathway inhibitor (LDN-193189), and WNT pathway inhibitor (IWP-2) at optimized concentrations and time points. These parameter changes enable transition from progenitor to terminally differentiated podocytes while maintaining expandability.
2Productivity
If podocyte cell lines are used as an alternative source, then large numbers of cells can be obtained, but they show poor differentiation potential or are of non-human origin
Solution Approach 1:
The patent segments the podocyte generation process into distinct stages: (1) generation of nephron progenitor cells from pluripotent stem cells, (2) differentiation of progenitors into podocytes, and (3) validation of human origin and differentiation potential. This segmentation allows each stage to be optimized independently, ensuring both high yield and reliability of terminally differentiated human podocytes.
Solution Approach 2:
The patent introduces nephron progenitor cells as an intermediary population between pluripotent stem cells and terminally differentiated podocytes. This intermediary stage serves as a bridge that maintains human origin and differentiation potential while enabling expansion of cell numbers, avoiding the limitations of direct podocyte isolation or use of transformed cell lines.
3Ease of operation
If serum is used in culture media, then cell growth is supported, but the differentiation into terminally differentiated podocytes is compromised
Solution Approach 1:
The patent employs serum-free culture conditions with chemically defined media components to create an inert environment that supports both cell growth and terminal differentiation. The serum-free media contains optimized concentrations of growth factors, inhibitors, and supplements that maintain cell viability while directing differentiation toward terminally differentiated podocytes without the interfering components present in serum.
Data Source
AI summary
Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.